Literature DB >> 33584689

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.

S Morteza Seyed Jafari1, Laurence Feldmeyer1, Simon Bossart1, Dagmar Simon1, Christoph Schlapbach1, Luca Borradori1.   

Abstract

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.
Copyright © 2021 Seyed Jafari, Feldmeyer, Bossart, Simon, Schlapbach and Borradori.

Entities:  

Keywords:  bullous pemphigoid; dupilumab; omalizumab; recalcitrant; treatment

Year:  2021        PMID： 33584689      PMCID： PMC7879677          DOI： 10.3389/fimmu.2020.611549

Source DB:  PubMed          Journal:  Front Immunol        ISSN： 1664-3224            Impact factor:   7.561


  12 in total

1.  Successful management of severe infant bullous pemphigoid with omalizumab.

Authors:  C Dufour; A L Souillet; C Chaneliere; F Jouen; C Bodemer; D Jullien; F Cambazard; P Joly; P Reix
Journal:  Br J Dermatol       Date:  2012-03-02       Impact factor: 9.302

2.  Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.

Authors:  Cristina Vico-Alonso; Alba Calleja-Algarra; Raquel Aragón-Miguel; Alba Sánchez-Velázquez; Virginia Velasco-Tamariz; Pablo Luis Ortiz-Romero; Verónica Monsálvez-Honrubia
Journal:  Dermatol Ther       Date:  2019-02-07       Impact factor: 2.851

3.  Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid.

Authors:  Alex Kaye; Samantha C Gordon; Sandhya C Deverapalli; Min Ji Her; David Rosmarin
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

4.  Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells.

Authors:  Y Teraki; T Hotta; T Shiohara
Journal:  J Invest Dermatol       Date:  2001-11       Impact factor: 8.551

Review 5.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors:  K A N Messingham; H M Holahan; J A Fairley
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

6.  IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.

Authors:  Talia James; Sam Salman; Brittany Stevenson; Christine Bundell; Gavin Kelly; David Nolan; Mina John
Journal:  Clin Immunol       Date:  2018-12-14       Impact factor: 3.969

7.  Dupilumab for bullous pemphigoid with intractable pruritus.

Authors:  Jason S Seidman; Dawn Z Eichenfield; Charisse M Orme
Journal:  Dermatol Online J       Date:  2019-11-15

8.  Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.

Authors:  Otobia G Dimson; George J Giudice; Chang Ling Fu; Francoise Van den Bergh; Simon J Warren; Marleen M Janson; Janet A Fairley
Journal:  J Invest Dermatol       Date:  2003-05       Impact factor: 8.551

9.  Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.

Authors:  Rana Abdat; Reid A Waldman; Valeria de Bedout; Annette Czernik; Michael Mcleod; Brett King; Samantha Gordon; Razzaque Ahmed; Anna Nichols; Marti Rothe; David Rosmarin
Journal:  J Am Acad Dermatol       Date:  2020-03-13       Impact factor: 11.527

10.  Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.

Authors:  S Morteza Seyed Jafari; Karolina Gadaldi; Laurence Feldmeyer; Nikhil Yawalkar; Luca Borradori; Christoph Schlapbach
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561
View more
  9 in total

Review 1.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.

Authors:  Mohsen Afarideh; Robert Borucki; Victoria P Werth
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

Review 2.  Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Authors:  Roberto Russo; Niccolò Capurro; Emanuele Cozzani; Aurora Parodi
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

3.  Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients.

Authors:  Xiuting Liu; Jianchi Ma; Xiaonan Qiu; Dan Hong; Liangchun Wang; Zhenrui Shi
Journal:  Eur J Dermatol       Date:  2021-12-01       Impact factor: 3.328

4.  Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Authors:  Si-Hang Wang; Ya-Gang Zuo
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

5.  Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.

Authors:  Marina Alexandre; Gérôme Bohelay; Thomas Gille; Christelle Le Roux-Villet; Isaac Soued; Florence Morin; Frédéric Caux; Sabine Grootenboer-Mignot; Catherine Prost-Squarcioni
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

Review 6.  Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms.

Authors:  Connor Cole; Keshavamurthy Vinay; Luca Borradori; Kyle T Amber
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

7.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

8.  Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Authors:  Yihua Zhang; Qiuyun Xu; Lihong Chen; Jiawen Chen; Jing Zhang; Ying Zou; Ting Gong; Chao Ji
Journal:  Front Immunol       Date:  2021-10-14       Impact factor: 7.561

Review 9.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.